Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 55: 1794-1800, 2009. First published July 2, 2009; 10.1373/clinchem.2009.129411
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2009.129411v1
55/10/1794    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Widera, C.
Right arrow Articles by Wollert, K. C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Widera, C.
Right arrow Articles by Wollert, K. C.
(Clinical Chemistry. 2009;55:1794-1800.)
© 2009 American Association for Clinical Chemistry, Inc.

Endocrinology and Metabolism

Circulating Concentrations of Follistatin-Like 1 in Healthy Individuals and Patients with Acute Coronary Syndrome as Assessed by an Immunoluminometric Sandwich Assay

Christian Widera1, Rüdiger Horn-Wichmann2, Tibor Kempf1, Kerstin Bethmann1, Beate Fiedler1, Sarita Sharma1, Ralf Lichtinghagen3, Holger Leitolf2, Boris Ivandic4, Hugo A. Katus4, Evangelos Giannitsis4 and Kai C. Wollert1,a

1 Department of Cardiology and Angiology, 2 Department of Gastroenterology, Hepatology, and Endocrinology, and 3 Department of Clinical Chemistry, Hannover Medical School, Hannover, Germany; 4 Department of Medicine III, University of Heidelberg, Heidelberg, Germany.

aAddress correspondence to this author at: Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. Fax +49-511-532-5307; e-mail wollert.kai{at}mh-hannover.de.

Background: Follistatin-like 1 (FSTL1) is a 308–amino acid secreted glycoprotein. Tissue levels of FSTL1 are induced in animal models and patients with chronic inflammatory and cardiovascular disease. We hypothesized that FSTL1 can be measured in the human circulation and used as a biomarker in acute coronary syndrome (ACS).

Methods: We developed an immunoluminometric assay (ILMA), assessed the preanalytic characteristics of FSTL1, and determined circulating FSTL1 concentrations in 120 apparently healthy individuals and 216 patients with ACS.

Results: The assay had a limit of detection of 0.17 µg/L, limit of quantification of 1.02 µg/L, intraassay imprecision of ≤12.7%, and interassay imprecision of ≤15.4%. Selectivity was demonstrated with size-exclusion chromatography and lack of cross-reactivity with related proteins. The assay was not appreciably influenced by unrelated biological substances. FSTL1 in serum or whole blood was stable at room temperature for 48 h and was resistant to 4 freeze-thaw cycles. Measured FSTL1 concentrations in citrated plasma and heparin-treated plasma were 18% and 17% lower, respectively, than concentrations measured in serum. Apparently healthy individuals presented with a median FSTL1 serum concentration of 7.18 (range 1.06–18.49) µg/L. Serum FSTL1 concentrations were increased in ACS and related to the risk of all-cause mortality during follow-up.

Conclusions: The ILMA permits detection of FSTL1 in human serum and plasma. We expect that the favorable preanalytic characteristics of FSTL1 and the reference limits defined here for apparently healthy individuals will facilitate future studies of FSTL1 as a biomarker in various disease settings, including ACS.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.